Geneos Therapeutics Revenue and Competitors

Location

$50M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Geneos Therapeutics's estimated annual revenue is currently $1.2M per year.(i)
  • Geneos Therapeutics's estimated revenue per employee is $77,500
  • Geneos Therapeutics's total funding is $50M.

Employee Data

  • Geneos Therapeutics has 15 Employees.(i)
  • Geneos Therapeutics grew their employee count by -25% last year.

Geneos Therapeutics's People

NameTitleEmail/Phone
1
ControllerReveal Email/Phone
2
VP, Research and DiscoveryReveal Email/Phone
3
VP, Research and DiscoveryReveal Email/Phone
4
VP, Quality Assurance - ManufacturingReveal Email/Phone
5
Chief Operating OfficerReveal Email/Phone
6
Consulting Chief Financial OfficerReveal Email/Phone
7
Consulting Chief Medical OfficerReveal Email/Phone
8
Consulting Chief Business OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.4M9-10%N/AN/A
#2
$7.1M4677%N/AN/A
#3
$14.4M9327%N/AN/A
#4
$0.9M60%N/AN/A
#5
$1.6M1043%N/AN/A
#6
$11.5M746%N/AN/A
#7
$0.9M1122%N/AN/A
#8
$3.7M24-8%N/AN/A
#9
$2M1318%N/AN/A
#10
$9.3M602%N/AN/A
Add Company

What Is Geneos Therapeutics?

At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer – your body’s own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies.

keywords:N/A

$50M

Total Funding

15

Number of Employees

$1.2M

Revenue (est)

-25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Geneos Therapeutics News

2022-03-22 - Geneos Therapeutics Secures $17 Million in Series A2 ...

At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our passion is to develop personalized...

2022-03-22 - Geneos Therapeutics Raises $17M in Series A2 Funding

The company intends to use the funds to expand the GT-30 Phase Ib/IIa clinical trial, its pipeline into a new indication, and continued...

2022-03-22 - Money on the Move: March 23-29

Part of the money will expand Geneos' GT-30 Phase Ib/IIa clinical trial for a personalized cancer vaccine, ... Harm Reduction Therapeutics.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M1633%N/A
#2
$2.5M1623%N/A
#3
$2.4M1623%N/A
#4
$3.4M2011%N/A
#5
$2.2M22-12%N/A